These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 26137024)

  • 1. Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience.
    Takai M; Yamauchi T; Matsuda Y; Tai K; Ikegaya S; Kishi S; Urasaki Y; Yoshida A; Iwasaki H; Ueda T
    Oncol Lett; 2015 May; 9(5):2119-2125. PubMed ID: 26137024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study.
    Takai M; Yamauchi T; Ookura M; Matsuda Y; Tai K; Kishi S; Yoshida A; Iwasaki H; Nakamura T; Ueda T
    Anticancer Res; 2014 Dec; 34(12):7287-96. PubMed ID: 25503162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
    Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
    Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
    Feng X; Dong K; Pham D; Pence S; Inciardi J; Bhutada NS
    J Clin Pharm Ther; 2013 Aug; 38(4):301-8. PubMed ID: 23550846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndrome.
    Takai M; Yamauchi T; Fujita K; Lee S; Ookura M; Kishi S; Urasaki Y; Yoshida A; Iwasaki H; Ueda T
    Oncol Lett; 2014 Oct; 8(4):1523-1527. PubMed ID: 25202361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome.
    Cairo MS; Thompson S; Tangirala K; Eaddy MT
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):173-178. PubMed ID: 27965022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia.
    Vachhani P; Baron J; Freyer CW; Miller A; Wetzler M; Thompson JE; Griffiths EA; Wang ES
    Leuk Res; 2021 Aug; 107():106588. PubMed ID: 33957371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase.
    Usami E; Kimura M; Iwai M; Teramachi H; Yoshimura T
    Mol Clin Oncol; 2017 Jun; 6(6):955-959. PubMed ID: 28588796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
    Vadhan-Raj S; Fayad LE; Fanale MA; Pro B; Rodriguez A; Hagemeister FB; Bueso-Ramos CE; Zhou X; McLaughlin PW; Fowler N; Shah J; Orlowski RZ; Samaniego F; Wang M; Cortes JE; Younes A; Kwak LW; Sarlis NJ; Romaguera JE
    Ann Oncol; 2012 Jun; 23(6):1640-5. PubMed ID: 22015451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
    McDonnell AM; Lenz KL; Frei-Lahr DA; Hayslip J; Hall PD
    Pharmacotherapy; 2006 Jun; 26(6):806-12. PubMed ID: 16716134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
    Vines AN; Shanholtz CB; Thompson JL
    Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention and treatment of hyperuricemia in hematological malignancies.
    Cairo MS
    Clin Lymphoma; 2002 Dec; 3 Suppl 1():S26-31. PubMed ID: 12521386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
    Gupta G; Seth T; Garg V; Juneja R; Mahapatra M; Datta SK; Upadhyay AD; Saxena R
    Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e99-e104. PubMed ID: 33039358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies.
    Yaman S; Başcı S; Turan G; Ulu BU; Yiğenoğlu TN; Dal MS; Kızıl Çakar M; Altuntaş F
    Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):e71-e76. PubMed ID: 34565690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
    Knoebel RW; Lo M; Crank CW
    J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective observational study of a low fixed-dose rasburicase protocol for the treatment of tumor lysis syndrome in adults.
    Hossain S; Naber M; Yacobucci MJ
    J Oncol Pharm Pract; 2022 Sep; 28(6):1326-1331. PubMed ID: 34115548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypouricemic effect and safety of febuxostat used for prevention of tumor lysis syndrome.
    Maie K; Yokoyama Y; Kurita N; Minohara H; Yanagimoto S; Hasegawa Y; Homma M; Chiba S
    Springerplus; 2014; 3():501. PubMed ID: 25279293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
    Coiffier B; Mounier N; Bologna S; Fermé C; Tilly H; Sonet A; Christian B; Casasnovas O; Jourdan E; Belhadj K; Herbrecht R;
    J Clin Oncol; 2003 Dec; 21(23):4402-6. PubMed ID: 14581437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase.
    Hummel M; Reiter S; Adam K; Hehlmann R; Buchheidt D
    Eur J Haematol; 2008 Apr; 80(4):331-6. PubMed ID: 18081720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single 6-mg dose of rasburicase: The experience in a large academic medical center.
    Nauffal M; Redd R; Ni J; Stone RM; DeAngelo DJ; McDonnell AM
    J Oncol Pharm Pract; 2019 Sep; 25(6):1349-1356. PubMed ID: 30111244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.